


GRANTED

(IN395354)

Orally active nanoformulation of lisofylline and composition thereof



NEED

Type 1 Diabetes treatments often require frequent dosing and exhibit poor oral bioavailability. This patent presents a nanoformulation that enhances stability, reduces dosing frequency, and improves bioavailability for more efficient treatment.

MARKET ANALYSIS

The global diabetes drug market is projected to grow at a CAGR of 6.3% from 2023 to 2033, driven by increased Type 1 diabetes prevalence and demand for innovative treatments. (Source: MarketsandMarkets, 2023)

TECHNOLOGY OVERVIEW

This oral nanoformulation combines Lisofylline-linoleic acid conjugate with an amphiphilic block co-polymer. It offers higher stability, reduced metabolism, and enhanced bioavailability compared to conventional treatments, enabling lower doses and less frequent administration.

Target Industries

1) Pharmaceutical companies specializing in diabetes; 2) Drug delivery system developers; 3) Research institutions focused on novel drug formulations.

TECHNOLOGY KEY FEATURES

Nanoformulation; encapsulated Lisofylline-linoleic acid conjugate; amphiphilic block co-polymer; particle size: 100-150 nm; reduced dosing frequency; improved stability and bioavailability.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure), SDG 12 (Responsible Consumption and Production)

[Read more here](#)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913